Kairos Pharma Launches Initial Public Offering
Kairos Pharma, Ltd. is thrilled to announce the pricing of its initial public offering of common stock, aiming to raise $6.2 million in gross proceeds. This IPO includes 1,550,000 shares priced at $4.00 each, plus an additional 232,500 shares that may be available through an option for underwriters. This significant step highlights the company's commitment to advancing innovative treatments for cancer.
Investing in Innovative Cancer Therapies
The funds generated from this public offering will be directly funneled into the company's clinical trials. Specifically, Kairos Pharma intends to use the proceeds to further its Phase 1 trial for lung cancer, as well as a Phase 2 trial focused on prostate cancer. These efforts will concentrate on their leading product candidate, ENV 105, which aims to combat drug resistance and enhance the effectiveness of current cancer therapies.
Company Overview and Therapeutic Pipeline
Basing its operations in Los Angeles, Kairos Pharma is at the cutting edge of biopharmaceutical development, especially in oncology. The company is dedicated to crafting therapies that not only target cancer cells but also boost the immune system's ability to fight cancer. Their innovative pipeline includes ENV 105 and other promising candidates, like KROS 101, which is designed to enhance T cell functions against tumors, underscoring the company's dedication to groundbreaking solutions.
Joining the NYSE American
The common stock has received approval for listing on the NYSE American under the ticker symbol "KAPA." Trading is expected to begin shortly after the offering concludes, paving the way for new investment opportunities and collaborations.
The Role of Underwriters in the Offering
For this public offering, Boustead Securities, LLC is the lead managing underwriter, with support from EF Hutton LLC. Their expertise plays a crucial role in navigating the intricacies of the financial markets and facilitating a successful IPO.
How Will the Funds Be Used?
The proceeds from this public offering will meaningfully expedite the progression of pivotal projects. The company's emphasis on reversing resistance to traditional therapies reveals its exceptional potential to transform treatment approaches in the field of oncology.
Regulatory Approvals and Future Steps
A Form S-1 registration statement related to the offering has been authorized by the Securities and Exchange Commission, which is a vital milestone for public visibility and compliance. This procedural framework assures transparency and reassures investors of the legitimacy of their investments.
Company Contact Information
For anyone interested in further communication or inquiries regarding the offering or the company's initiatives, please reach out to CORE IR, specifically Louie Toma at investors@kairospharma.com.
Frequently Asked Questions
What is the purpose of the IPO for Kairos Pharma?
The IPO aims to raise funds to support clinical trials and develop innovative cancer therapies, including ENV 105.
When will the stock begin trading?
Trading of Kairos Pharma's common stock is expected to begin shortly after the conclusion of the offering under the ticker symbol "KAPA."
How much capital is Kairos Pharma raising through the IPO?
Kairos Pharma is seeking to raise approximately $6.2 million in gross proceeds from the initial public offering.
Who are the underwriters for the offering?
Boustead Securities, LLC is the lead managing underwriter, with assistance from EF Hutton LLC for the IPO.
What is the main focus of Kairos Pharma's research?
Kairos Pharma focuses on developing therapies that tackle cancer drug resistance and enhance the immune system's response to cancer treatments.
